AIM ImmunoTech (AIM) Non Operating Investment Income (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Non Operating Investment Income came in at -$1000.0 in Q1 2026, down 103.7% YoY from $27000.0 in Q1 2025, and little changed on a QoQ basis from -$1000.0 in Q3 2025.
AIM ImmunoTech (AIM) Non Operating Investment Income (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 15 years of Non Operating Investment Income data on file, last reported at -$1000.0 in Q1 2026.
- Quarterly Non Operating Investment Income fell 103.7% year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11000.0 (down 142.31% YoY) and the FY2025 annual result came in at $17000.0, up 118.28% from the prior year.
- Non Operating Investment Income held at -$1000.0 in Q1 2026, from -$1000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $401000.0 in Q4 2023 to a low of -$934000.0 in Q1 2022.
- A 5-year average of -$97250.0 and a median of -$47000.0 in 2024 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income jumped 345.56% — and 2024, when it slumped 147.13%.
- Tracing AIM's Non Operating Investment Income over 5 years: stood at $90000.0 in 2022, then jumped by 345.56% to $401000.0 in 2023, then tumbled by 147.13% to -$189000.0 in 2024, then jumped by 99.47% to -$1000.0 in 2025, then changed by 0.0% to -$1000.0 in 2026.
- The last three Non Operating Investment Income figures came in at -$1000.0 (Q1 2026), -$1000.0 (Q3 2025), and -$9000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | -189,000.00 |
| Dec 31, 2024 | -189,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | -85,000.00 |
| Jun 30, 2024 | -85,000.00 |
| Mar 31, 2024 | -92,000.00 |
| Mar 31, 2024 | -92,000.00 |
| Dec 31, 2023 | 401,000.00 |
| Dec 31, 2023 | 401,000.00 |